HAE Stock Haemonetics Corporation
STRONG BUY US · NYSEBlood-management demand and favorable analyst coverage support continued operational momentum.
Future value: $140.00 (+17.46%) · 6-12 months
Signal breakdown
- ▸Multiple analysts maintained Buy ratings with targets above market.
- ▸Above 50-day MA (+9.7%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (93.9% of range) — strength
Is HAE a buy right now?
Trend: HAE is trading above the 50-day average (+9.70%), RSI 61 — neutral momentum, with a 3-month return of +44.40%.
Valuation & quality: Haemonetics Corporation trades on a trailing P/E of 57.3, forward P/E 20.6, PEG 1.88, price-to-book 6.47; fundamentals show net margin 7.1%, return on equity 11.2%, revenue growth 5.6% year on year.
Analyst consensus: 10 analysts have a mean 12-month price target of $124.50 (+4.5% vs the last close; range $86.00 – $142.00), consensus rating “buy”.
Our screen: STRONG BUY (score 5) — Blood-management demand and favorable analyst coverage support continued operational momentum.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -11.00% | +6.60% | +12.80% | +10.60% | +14.10% | +20.50% | +2.20% | +13.20% |
Fundamentals
Analyst price target
Technical signals
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Sector: Healthcare · Industry: Medical Devices · United States · 3,009 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.